Brainstorm Cell Therapeutics Files 2024 10-K
Ticker: BCLI · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biotechnology
TL;DR
Brainstorm Cell Therapeutics 2024 10-K is in: $226.6M assets, $6M liabilities. Check it out.
AI Summary
Brainstorm Cell Therapeutics Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in New York, operates in the biological products sector. Key financial figures from the filing include total assets of $226.64 million and total liabilities of $6.00 million.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Brainstorm Cell Therapeutics' financial health and operational status for the fiscal year 2024.
Risk Assessment
Risk Level: medium — The company operates in the biotechnology sector, which is inherently high-risk due to the long development cycles, regulatory hurdles, and clinical trial outcomes.
Key Numbers
- $226.64M — Total Assets (Financial position as of December 31, 2024.)
- $6.00M — Total Liabilities (Financial obligations as of December 31, 2024.)
- 2.31 — Current Ratio (Indicates short-term liquidity.)
- 6.00 — Debt-to-Equity Ratio (Measures financial leverage.)
- 0.067 — Price-to-Earnings Ratio (Valuation metric, though may not be meaningful if unprofitable.)
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 1325 AVENUE OF AMERICAS (address) — Business Address
- NEW YORK (location) — Business Address City
- DE (location) — State of Incorporation
- $226,636,000 (dollar_amount) — Total Assets
- $6.00 (dollar_amount) — Total Liabilities
FAQ
What is the company's primary business activity?
Brainstorm Cell Therapeutics Inc. is primarily involved in Biological Products (No Diagnostic Substances).
What was the company's total asset value at the end of the fiscal year 2024?
The company reported total assets of $226,636,000 as of December 31, 2024.
What is the company's reported total liabilities as of December 31, 2024?
Total liabilities for Brainstorm Cell Therapeutics Inc. were $6.00 million as of December 31, 2024.
Where is Brainstorm Cell Therapeutics Inc. incorporated and headquartered?
The company is incorporated in Delaware (DE) and its business address is in New York, NY.
What are some of the key inputs used in the fair value measurement of the July 2023 Warrants?
Key inputs include share price, risk-free interest rate, price volatility, and maturity, all categorized under FairValueInputsLevel3Member.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).